IMCR Immunocore: Projected Price to Earnings

IMCR (Immunocore Holdings plc) - company brandmark

Reliance on a single drug creates vulnerability to new therapies, yet Immunocore Holdings plc (IMCR) maintains high course pricing due to its monopoly status in melanoma treatment. The company's forward P/E ratio clearly demonstrates this interaction, with the current metric standing at 0.00. Successful drug sales are steering the business toward self-sufficiency, stabilizing cash flows and improving the bottom line.

immunocore.com - IMCR Future Price to Earnings Multiple (period 07/04/2022 - 11/18/2026)

Metric breakdowns and analytics for immunocore.com (IMCR)

Fundamental company analysis:Immunocore Holdings IMCR
Signature product of Immunocore Holdings plc

Forward P/E measures the equity value of an asset by comparing market demand with projected net income, excluding exchange distortions. This metric is calculated as the ratio of current market capitalization to expected earnings, demonstrating sensitivity to future financial results. By analyzing the expected P/E level of Immunocore Holdings plc (IMCR), an investor assesses the balance between the growth premium and the risk of correction. The trend of this indicator confirms market optimism regarding Bakhtiyar Karimi's strategy. Management's expertise in immuno-oncology and the launch of new drugs justify the high valuation of future revenues for Immunocore Holdings plc (IMCR).

Analysis of competing companies

Forward P/E Multiple IBRX|Janux Therapeutics (JANX) - Forward Price to Earnings Multiple|Arcus Biosciences Inc - Projected Price to Earnings|Zymeworks (ZYME) - Projected Price to Earnings Ratio|TNGX: Projected Price to Earnings|Future Price to Earnings Multiple IOVA (Iovance Biotherapeutics, Inc.)|IMTX: Forward P/E Multiple|XNCR - Market Cap to Projected Earnings|Future Price to Earnings compasstherapeutics.com|Projected Price to Earnings replimune.com (REPL)|Future Price to Earnings Lyell (LYEL)|Projected Price to Earnings Innate Pharma, S.A. IPHA|Pyxis Oncology Inc. - Projected Price to Earnings|Forward P/E Multiple Compugen Ltd. CGEN|IOBT - Future Price to Earnings|STRO (sutrobio.com) - Price to Future Earnings Ratio|MiNK Therapeutics, Inc (INKT) - Future Price to Earnings|Projected Price to Earnings Ratio Werewolf Therapeutics (HOWL)|Projected Price to Earnings IMMX|ALXO - Forward Price to Earnings Multiple|Forward P/E Multiple CUE|Market Cap to Future Earnings Ratio PDSB|Forward P/E Multiple SONN (Sonnet BioTherapeutics)|Future Price to Earnings Multiple MAIA|liminatuspharma.com - Forward P/E Multiple|Projected Price to Earnings Ratio LAVA Therapeutics|NextCure, Inc. (NXTC) - Future Price to Earnings|Leap Therapeutics Inc - Future Price to Earnings Multiple|INTS (Intensity Tx) - Forward P/E Multiple|Forward P/E Multiple senseibio.com|Future Price to Earnings Theriva Biologics (TOVX)|GRTS: Price to Expected Earnings Ratio|Forward P/E Multiple KA (kinetabio.com)|neximmune.com (NEXI) - Projected Price to Earnings Ratio|TSBX: Projected Price to Earnings|VCNX: Future Price to Earnings|HARP: Forward P/E Multiple